Clear ×
Polaryx Therapeutics, Inc. PLYX

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 1, 2026 8-K 7 signals fired
Other
Executive Educational Background Disclosure Kol Endorsement Executive Transition Gratitude Statement Enrollment Ahead Of Schedule Interim Data Positive
Core
Lead Asset Progress Indication Expansion
Aug 13, 2026 10-Q 14 signals fired
Other
Financing Activities Cash Flow Disclosure Net Loss Reported Personnel Cost Decrease Disclosure Emerging Growth Company Status Disclosed Capital Raising Uncertainty Disclosed Valuation Allowance Deferred Tax Disclosure Operating Lease Rent Expense Disclosed Shares Outstanding Disclosure Institutional Investment Protocol Amended Significant Accounting Estimates Disclosure Administrative Efficiency Acquisition And Management Fees Disclosed Burn Rate Controlled
Jul 21, 2026 8-K 2 signals fired
Core
Management Exodus
Other
Successor Agent Appointment Provision
Jul 17, 2026 8-K 2 signals fired
Other
Record Date Disclosure Annual Meeting Notice Disclosure
May 28, 2026 8-K 18 signals fired · top 15
Other
Corporate Organization And Standing Representation Amendment Modification Waiver Clause Nyse Listing Disclosure Non Assignment Clause Closing Logistics Specified Gene Therapy Aav Closing Deliverables Specified Institutional Investment Survival Of Representations Warranties Clause Safety Differentiated Ipo Or Capital Raising Completion
Core
Combination Therapy Mentioned Lead Asset Progress Indication Expansion
Biotech v3
Ai Drug Discovery Investment
May 15, 2026 10-Q 22 signals fired · top 15
Other
Net Loss Reported Financing Activities Cash Flow Disclosure Equity Award Plan Types Enumerated Emerging Growth Company Status Disclosed Deferred Tax Asset Valuation Disclosure Capital Raising Uncertainty Disclosed Segment Aggregation Disclosure Equity Plan Share Reserve Disclosure Nyse Listing Disclosure Share Repurchase Activity Disclosed Valuation Allowance Deferred Tax Disclosure Liquidity Position Snapshot Disclosed Operating Lease Rent Expense Disclosed Shares Outstanding Disclosure
Core
Indication Expansion